Motif Bio PLC is a United Kingdom-based clinical-stage biopharmaceutical company which specializes in developing antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, Iclaprim, and MTF-001, a preclinical program.-based on iclaprim and other lead compounds, the Company is engaged in the development of a lead series with the objective of identifying a DHFRi that is effective against a broad spectrum of gram positive bacteria, including those resistant to available antibiotics, that can be administered once daily in injectable (I/V) and oral (pill) formulations. The Company's other programs include programs in various-stages of development by building a portfolio of antibiotics by licensing drug candidates from organizations specialized in antibacterial research.
London, GB
Size (employees)
4 (est)+300%
Motif Bio is headquartered in London, GB
Report incorrect company information

Motif Bio Office Locations

Motif Bio has offices in London and New York
London, GB (HQ)
1 Tudor St
New York, US
2622 125 Park Ave
Show all (2)
Report incorrect company information

Motif Bio Financials and Metrics

Motif Bio Financials


Net income (FY, 2017)

(31.9 m)

EBITDA (FY, 2017)

(27.1 m)

EBIT (FY, 2017)

(27.1 m)

Market capitalization (31-Oct-2017)

107.1 m

Closing share price (31-Oct-2017)


Cash (31-Dec-2017)

16.1 m
Motif Bio's current market capitalization is £107.1 m.
GBPFY, 2014FY, 2015FY, 2016FY, 2017


(749.9 k)(6.3 m)(28.2 m)(27.1 m)


(749.9 k)(6.3 m)(28.2 m)(27.1 m)

Pre tax profit

(810.8 k)(6.5 m)(28.7 m)(31.9 m)

Income tax expense

(599.3 )(587.1 )(204.5 )(15.7 k)
GBPFY, 2014FY, 2015FY, 2016FY, 2017


2.2 k21.7 m15.6 m16.1 m

Accounts Receivable

8.2 k

Current Assets

154.6 k21.8 m15.8 m16.4 m


4.2 m
GBPFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(811.4 k)(6.5 m)(28.7 m)(31.9 m)

Cash From Operating Activities

(1.1 k)(6.1 m)(19.9 m)(26.7 m)

Cash From Financing Activities

3.4 k27.8 m15.3 m27.4 m

Net Change in Cash

2.2 k21.7 m(4.6 m)726.3 k
GBPY, 2017

Financial Leverage

-3.3 x
Show all financial metrics
Report incorrect company information

Motif Bio News and Updates

Hospital Acquired Pneumonia (HAP) Key Players - Motif Bio Plc, Nabriva Therapeutics plc, Polyphor Ltd, and Shionogi & Co Ltd Market Analysis & Forecast 2018 to 2022 with their unique quality of simplifying the market research study, presents a deep diving study report “Hospital Acquired Pneumonia - Pipeline Review, H1 2018” Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information